CD36 and metabolic dysfunction-associated steatotic liver disease: Clinical studies have shown that dysregulated expression of hepatic CD36 was significantly associated with insulin resistance, hyperinsulinemia, and increased steatosis in patients with NAFLD and chronic hepatitis C [32].